Barclays
MEDS

Barclays’s DataMeds AI MEDS Stock Holding History

Barclays’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24K Buy
+723
New +$3.56K ﹤0.01% 4861

Other funds holding MEDS

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Barclays's MEDS Position: Q2 2026 in Review

Barclays opened a new position in DataMeds AI (MEDS) in Q2 2026: 723 shares worth $2.24K. The stake represents ﹤0.01% of the portfolio and ranks #4861 among its holdings.

10 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

  • Barclays held 723 shares of DataMeds AI worth $2.24K as of Q2 2026.
  • DataMeds AI was a new Barclays position in Q2 2026.
  • DataMeds AI made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4861 holding.
  • 10 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.